Source comparison
CJC-1295 No DAC vs Ipamorelin vs Sermorelin — Key Differences
Research conducted at the University of Arizona College of Medicine found that combining CJC-1295 (without DAC modification) with Ipamorelin produced mean IGF-1 increases of 35–52% above baseline in healthy adults. Outperforming either peptide alone without th
This comparison does not assign a generated winner or score.
- Research conducted at the University of Arizona College of Medicine found that combining CJC-1295 (without DAC modification) with Ipamorelin produced mean IGF-1 increases of 35–52% above baseline in healthy adults. Outperforming either peptide alone without the cortisol or prolactin spikes seen with older growth hormone secretagogues like GHRP-2 or GHRP-6. The mechanism matters: CJC-1295 no DAC acts as a GHRH (growth hormone-releasing hormone) analogue that amplifies natural GH pulses, while Ipamorelin functions as a ghrelin mimetic that selectively triggers somatotroph cells in the pituitary to release GH. Sermorelin, also a GHRH analogue, operates through the same pathway as CJC-1295 but with a significantly shorter half-life. Roughly 10–20 minutes versus several hours.
- Our team has worked with hundreds of researchers navigating peptide selection for growth hormone studies. The confusion typically centres on one question: if all three peptides elevate GH, why does the mechanism matter? It matters because half-life, receptor selectivity, and pulsatility patterns determine both efficacy windows and side effect profiles.
- What's the difference between CJC-1295 no DAC, Ipamorelin, and Sermorelin?
- CJC-1295 no DAC is a modified GHRH analogue with a half-life of approximately 6–8 hours that amplifies endogenous GH pulses without suppressing natural rhythm. Ipamorelin is a ghrelin receptor agonist with high selectivity for GH release, producing discrete secretory bursts with a half-life near 2 hours and zero cortisol or prolactin elevation. Sermorelin is an unmodified GHRH fragment (amino acids 1–29) with a half-life of 10–20 minutes, designed to mimic natural hypothalamic signalling but requiring more frequent dosing to maintain therapeutic effect.
- The critical distinction most guides miss: CJC-1295 no DAC and Sermorelin both work upstream at the hypothalamic-pituitary axis by binding GHRH receptors on somatotrophs, while Ipamorelin works through the ghrelin receptor (GHSR-1a) on the same cells. A completely different signalling cascade. This is why combination protocols exist: stacking a GHRH analogue with a ghrelin mimetic produces synergistic GH release that neither achieves alone. This article covers exactly how each peptide's receptor mechanism drives its clinical profile, how half-life determines dosing strategy, and what preparation mistakes researchers make that compromise study outcomes.